The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2024 | DESTINY-Gastric03: T-DXd in HER2+ and HER2-low gastric cancer
Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the evolving landscape of treatment for HER2-positive metastatic gastric cancer. She emphasizes the significant progress made with antibody-drug conjugates (ADCs), drawing insights from their success in bladder cancer and other diseases. The Phase Ib/II DESTINY-Gastric03 (DG-03) trial (NCT04379596) employs trastuzumab deruxtecan, a HER2 ADC with a high drug-to-antibody ratio, in combination with anti-PD-1 therapy, initially using pembrolizumab. The study explores various bispecific antibodies, including combinations with CTLA-4 and PD-1 TIGIT. Additionally, the integration of capecitabine, a pivotal component in gastric cancer treatment, is being explored to enhance outcomes. The goal is to advance ADCs from later lines to first-line therapy, providing a comprehensive and improved approach for HER2-positive metastatic gastric cancer. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
